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A 20-year-old man was shown to have a deficiency of carnitine palmitoyltransferase (CPT) II in skeletal muscle. The 
evidence was: (i) there was no significant oxidation of [9,10 -3 H]palmitate or of[1-14C]palmitate in mitochondrial fractions 
from fresh skeletal muscle from the patient; (ii) all the CPT activity in a homogenate of fresh muscle from the patient 
was overt (CPT I) with no increase in activity after the inner membrane was disrupted; (iii) all the CPT activity in the 
patient's muscle was inhibited by malonyl-CoA; and (iv) an immunoreactive p ptide of 67 kDa corresponding to CPT 
II, present in mitochondria from controls, was absent in those from the patient. 
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1. INTRODUCTION 
The mitochondrial oxidation of long-chain fatty 
acids involves the formation of their CoA esters in 
the outer mitochondrial membrane and the en- 
doplasmic reticulum. In the presence of carnitine 
their acyl groups are then transferred to CoA in the 
matrix by the concerted action of CPT I, the car- 
nitine/acylcarnitine exchange carrier and CPT II. 
CPT II is located on the inner face of the inner 
membrane [1] and it was believed that CPT I is 
located on the outer face [11, and that CPT ! and 
CPT II are the same protein with different kinetic 
properties due to their different locations in the 
mitochondrion [2]. However, recent work in- 
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dicates that CPT I in skeletal muscle and liver 
mitochondria is located in the outer mitochondrial 
membrane and is a different protein from CPT II 
[3-8]. CPT I, but not CPT II, is inhibited by 
malonyl-CoA [4]. 
CPT deficiency is an uncommon cause of muscle 
disease in man. Patients with impaired CPT activi- 
ty in skeletal muscle normally present with pain 
after prolonged exercise often associated with 
myoglobinuria [9]. Because of the variety of assay 
procedures used it is often uncertain, however, 
whether other workers have measured CPT I, CPT 
II or both (see [10,11]). Here, we report a case of 
unequivocal CPT II deficiency in human muscle. 
2. MATERIALS AND METHODS 
2.1. Case h&tory 
A 20-year-old male medical student was referred to Newcastle 
for investigation. He presented with a history of exertional mus- 
cle pain and myoglobulinuria. Ingestion of carbohydrate re- 
lieved the severity of his symptoms, suggesting a defect of fatty 
acid oxidation in skeletal muscle. Histologically his skeletal 
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muscle was normal except for a minor excess of neutral ipid. 
A defect of the respiratory chain was excluded [11]. 
2.2. Materials 
Most biochemicals were obtained from Sigma (Poole, 
Dorset) and BCL (Lewes, Sussex). Malonyl-CoA was obtained 
from PL Biochemicals (Milwaukee, WI). L-Carnitine was a gift 
from Sigma-tau (Rome). l-L-[methyl-3H]Carnitine, 1-DL- 
[methyl-~4C]carnitine, [1-t4C]palmitate and [9,10-3H]palmitate 
were obtained from Amersham International (Amersham, 
Bucks). Labelled carnitine was dissolved in 1.0 M HCI and ex- 
tracted 5 times with isobutanol to remove background radioac- 
tivity. Palmitoyl-CoA and palmitoyl-DL-[~4C]carnitine w re 
prepared and characterised [12]. Antibody to bovine liver CPT 
II (latent CPT) was raised in rabbits and precipitated from im- 
mune serum with (NH4)2804 [3]. 
2.3. Preparation of homogenates and mitochondrial fractions 
from skeletal muscle 
Samples of muscle (1-5 g) were obtained from the left vastus 
lateralis from the patient and from subjects with no evidence of 
muscle disease, and used immediately or stored at -85°C .  
2.3.1. Mitochondrial fractions 
Mitochondrial fractions were prepared from 3-5 g fresh 
muscle in a KCl-based medium [13]. The respiratory control 
ratios measured with 10 mM glutamate plus 1 mM malate as 
substrate [11] were in the range 3-5. Protein was determined by 
a modified Lowry method [11]. 
2.3.2. Homogenates 
Fresh or frozen muscle (0.1-0.8 g) was disrupted using a 
Polytron homogeniser for 5 s with a rheostat setting of 9 in 
12 vols of 50 mM potassium phosphate, 100 mM KCI, 5 mM 
MgC12, 1 mM EGTA, 1 mM ATP (pH 7.6) at 0°C. Samples of 
homogenates of fresh muscle were freeze-thawed 3 times to ex- 
pose CPT II. Citrate synthase activity [11] was increased by 
over 90°7o indicating that most mitochondria were intact before 
freeze-thawing. Citrate synthase activity was not increased fur- 
ther by 0.1070 Triton X-100 (v/v). 
2.4. Assay of/?-oxidation 
Incubations were carried out at 30°C and pH 7.0 in 1.0 ml of 
110 mM KC1, 10 mM Hepes, 5 mM MgC12, 10 mM potassium 
phosphate, 5 mM ATP,  1 mM L-carnitine, 100,uM CoA, 
1 mM EGTA, 0.2 mg cytochrome c and mitochondrial frac- 
tions (0.3-0.6 mg protein) and the reaction was initiated with 
0.12 mM palmitate containing 22 kBq [9,10-3H]palmitate nd 
3 kBq [1-t4C]palmitate complexed to defatted bovine serum 
albumin in a molar ratio of 5 : 1. Incubations were quenched by 
the injection of  200,ul of 5 M HCIO4, followed by 100,ul of 
0.5 M KHCO3. The 14CO2 and [14C]acetylcarnitine formed 
were measured [13]. A sample of the acid-quenched medium 
was centrifuged at 10000 × g for 10 min, and the supernatant 
adjusted to pH 12 with 2 M KOH and left at 20°C for 45 rain 
to hydrolyse labelled acetylcarnitine formed. The solution was 
then neutralised with 1.2 M HC1 and passed down a 0.5 ml 
Dowex I column (acid form, 200 mesh). The eluant, which con- 
tained only the 3HzO formed, was counted. The release of 3H20 
from [9,10-3H]palmitate is a good indicator of the flux through 
B-oxidation [14]. 
2.5. Assay of carnitine palmitoyltransferase activities 
2.5.1. Forward assay 
CPT activity was measured in the direction of palmitoylcar- 
nitine formation essentially as described by Zierz and Engel 
[15]. Muscle homogenate (50/A) was added to 100mM 
potassium phosphate, 2 mM KCN, 1 mM dithiothreitol, 80 gtM 
palmitoyl-CoA and 2.5 mM 1-L-[methyl)H]carnitine 
(18.5 kBq) and 0.1% (w/v) of defatted bovine serum albumin 
in a final volume of 1.0 ml at 30°C and pH 7.6. After an ap- 
propriate time the reaction was stopped by adding 1.0 ml of 
1.2 M HC1 at 0°C. Palmitoyl[14C]carnitine (2 kBq) was added 
as an internal standard. Palmitoyl[3H]carnitine formed and the 
palmitoyl[14C]carnitine standard were extracted into 2.0 ml of 
water-saturated isobutanol by shaking for 10 min and then cen- 
trifugation at 2000 rpm for 5 min. The isobutanol ayer was 
washed twice with 5 ml isobutanol-saturated water to remove 
free [3H]carnitine, and 1.0 ml was added to 8 ml scintillant 
(NE260 general purpose, Nuclear Enterprises, Sighthill, Edin- 
burgh) and counted for 3H and ~4C using a dual-channel pro- 
gramme. The internal standard confirmed that the extraction of 
labelled palmitoylcarnitine was complete (99 + 1.7%, mean _+ 
SD, n = 18). The reaction was linear for 10 min with all 
preparations. 
For determination of malonyl-CoA inhibition of CPT activi- 
ty, the assay was scaled down to a final volume of 0.1 ml con- 
taining 2.5 mM [3H]carnitine (18.5 kBq). 
2.5.2. Isotope exchange assay 
This assay depends on the rate of incorporation of [3H]car- 
nitine into a pool of palmitoylcarnitine in the presence of CoA 
[15]. The assay medium (final volume 1.0 ml at 30°C) was the 
same as that used for the forward assay except that the 
substrates were 2.5 mM L-[3H]carnitine (18.5 kBq), 100/~M or 
0.5 mM palmitoylcarnitine and 0.2 mM CoA. The reaction was 
started by addition of homogenate and stopped by 1.2 M HCI. 
The assay was linear for 20 rain. 
2.6. Immunoblot analys& 
The proteins in mitochondrial fractions were separated on 
10% SDS-polyacrylamide gels [16] and then transferred to 
nitrocellulose paper [17] with 0.1% SDS (w/v) in the transfer 
buffer, lmmunoreactive peptides were visualised by the im- 
munoperoxidase method [18] using antiserum to CPT II diluted 
1 : 1000 with 50 mM Tris, 0.15 M NaCI (pH 7.4). 
3. RESULTS 
3.1. /3-Oxidation 
There  was  v i r tua l ly  no  ox idat ion  o f  
[9 ,10-3H]pa lmi ta te  by  ske le ta l  musc le  mi tochon-  
d r ia l  f rac t ions  f rom the  pat ient  compared  w i th  
those  f rom the  cont ro l s  ( f ig . l ) ;  the  very  low ra te  
detected  may have  been  due  to  contaminat ing  
mic roperox isomes  [19]. No  s ign i f i cant  fo rmat ion  
o f  [14C]acety lcarn i t ine  (pat ient ,  0 .20  nmol .  min -  1. 
mg prote in - t ;  cont ro l s ,  16.8 _+ 2 .2 ,  mean + SD,  n 
= 3) o r  o f  14CO2 was  observed  (pat ient ,  
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Fig.2. Carnitine palmitoyltransferase activities in fresh and 
freeze-thawed skeletal muscle homogenates measured in the 
direction of palmitoylcarnitine formation. 
3.2. Carnitine palmitoyltransferase activities 
3.2.1. Forward assay 
CPT activity was similar in homogenates of 
fresh muscle from the patient and controls in 
which the mitochondria were mainly intact (fig.2). 
By contrast, the activity in control homogenates 
increased by a third after freeze-thawing while it 
did not increase in the homogenates of muscle 
from the patient (fig.2). CPT activity in intact 
mitochondria is due to CPT I while that in 
disrupted mitochondria is due to CPT I plus CPT 
II [1]. 
CPT I is strongly inhibited by malonyl-CoA 
while CPT II is insensitive [4]. Malonyl-CoA vir- 
tually abolished CPT activity in freeze-thawed 
homogenates of muscle from the patient, but only 
halved that in homogenates of control muscle 
(fig.3). 
3.2.2. Exchange assay 
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Fig.3. Effect of malonyl-CoA on carnitine palmitoyltransferase 
activities measured in the direction of palmitoylcarnitine 
formation in freeze-thawed homogenates of skeletal muscle. 
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Fig.4. Immunoblot analysis of CPT II. Human skeletal muscle 
mitochondrial muscle proteins (200 gg) we, re separated bySDS- 
polyacrylamide g lelectrophoresis and immunoblotted. Lane: 
ST, molecular mass tandards (kDa); C, control; P, patient. A
band corresponding to CPT I1 present in mitochondria from 
the control was absent in those from the patient. A band 
corresponding to CPT II was also present in skeletal muscle 
mitochondria from another individual (not shown). 
measured in freeze-thawed homogenates were: (us- 
ing 0.1 mM palmitoylcarnitine) patient, 0.46; con- 
trols, 0.59 __ 0.09 (means _+ SD, n = 8); (using 
0.5 mM palmitoylcarnitine) patient, 0.13; con- 
trols, 0.68 _+ 0.10). 
3.3. Immunoblot analysis of CPT H 
An immunoreactive peptide of molecular mass 
67 kDa corresponding to CPT II [8] was detected 
in skeletal muscle mitochondrial fractions from a 
control but was not in the fraction from the patient 
(fig.4). In contrast, an unidentified immunoreac- 
tive peptide of 56 kDa was present in similar 
amounts in mitochondria from both control and 
patient. 
4. DISCUSSION 
Our results unambiguously demonstrate the 
absence of CPT II activity and immunologically 
active CPT II in skeletal muscle from our patient 
and provide further vidence that CPT I and CPT 
II are different proteins in skeletal muscle. The in- 
ability of mitochondrial preparations from the pa- 
tient's muscle to oxidise palmitate can be explained 
by the defect of CPT II activity, although CPT I 
activity was apparently normal. 
There are several reports of CPT deficiency in 
muscle (see [11,12]); of these, one case was thought 
to be a defect of CPT I and a number to be defects 
of CPT II [10,20-28]. The interpretation of these 
reports is often uncertain because of the different 
assays used. High concentrations of palmitoylcar- 
nitine, usually included in the exchange assay 
(>0.5 raM) and routinely in hydroxamate assays 
(>4 raM), inhibit CPT I [11,12]. Low activity due 
to deficiency of CPT II may therefore be inter- 
preted as a combined deficiency. Most workers 
have used frozen samples of muscle and CPT ac- 
tivities in preparations from fresh and frozen mus- 
cle do not appear to have been compared in 
previous studies (fig.2). 
Some workers have measured CPT by both for- 
ward and exchange assays. Scholte et al. measure 
CPT I and CPT II selectively in disrupted 
mitochondria. CPT I is assayed in the forward 
direction with 10/~M palmitoyl-CoA and 0.25 mM 
L-carnitine as substrates, when only CPT I is 
measured because of its low Km for carnitine [11]. 
The exchange assay measures both CPT I and CPT 
II at low concentrations (< 50/~M) of 
palmitoylcarnitine, however, at > 0.7 mM, and in 
the presence of 2.5 mM carnitine, most of the ac- 
tivity is due to CPT II [11]. Zierz and Engel 
assayed CPT in muscle homogenates from 7 cases 
of CPT deficiency after freeze-thawing and sonica- 
tion using both the forward and exchange assays 
employing a range of palmitoyl-CoA and 
palmitoylcarnitine concentrations. They assumed 
that CPT I and CPT II are the same protein and 
concluded that there is a defective form of CPT 
with altered kinetics which is abnormally sensitive 
to inhibition by detergents, palmitoyl-CoA, 
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pa lmi toy lcarn i t ine  and  malony l -CoA,  ra ther  than  
the  presence  o f  normal  CPT  I and  absence  o f  CPT  
II [17]. 
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